8-K: Akebia Therapeutics Q1 2026 Results: Vafseo Growth Continues

Akebia Therapeutics reported Q1 2026 financial results, showing Vafseo net product revenues of $15.8 million and a 60% increase in treated patients, alongside progress in its kidney disease pipeline.

Summary

• Akebia Therapeutics reported first quarter 2026 financial results, with total revenues of $53.5 million, a decrease from $57.3 million in Q1 2025, primarily due to lower Auryxia revenues.
• Vafseo (vadadustat) net product revenues increased to $15.8 million in Q1 2026, up from $12.0 million in Q1 2025.
• The number of patients treated with Vafseo increased by approximately 60% in Q1 2026 compared to Q4 2025, with the highest number of new patient starts since launch.
• Total net product revenues for Q1 2026 were $52.0 million, comprising $15.8 million from Vafseo and $36.2 million from Auryxia.
• Research and development expenses increased to $14.8 million in Q1 2026 from $9.8 million in Q1 2025, driven by clinical trial activities for praliciguat and AKB-9090.
• Selling, general, and administrative expenses rose to $30.4 million in Q1 2026 from $25.7 million in Q1 2025.
• The company reported a net loss of $9.1 million for Q1 2026, compared to a net income of $6.1 million in Q1 2025.
• Cash and cash equivalents stood at $162.6 million as of March 31, 2026, with the company expecting sufficient resources for at least two years.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong growth in Vafseo sales and patient numbers, alongside promising pipeline developments. However, the overall revenue decline and net loss temper the positive sentiment.

Positives

• Vafseo net product revenues grew to $15.8 million in Q1 2026, a significant increase from $12.0 million in Q1 2025.
• The total number of patients treated with Vafseo increased by approximately 60% in Q1 2026 compared to Q4 2025.
• New patient starts for Vafseo in Q1 2026 were the highest in any quarter since its launch.
• The number of Vafseo prescribers increased by approximately 28% in Q1 2026 compared to Q4 2025.
• First refill adherence rates for Vafseo through March were approximately 86% for patients on an observed dosing protocol.
• Economic analysis presented showed Vafseo-treated patients had fewer hospitalization events (7.7%), fewer hospitalization days (16.0%), and lower annual hospitalization costs (14.8%) compared to darbepoetin alfa.
• A post-hoc analysis of the INNO2VATE program showed Vafseo demonstrated statistically significant better outcomes relative to darbepoetin alfa on a composite endpoint of all-cause mortality and hospitalization.
• The company expects its existing cash resources to fund its operating plan for at least two years.

Negatives

• Total revenues decreased to $53.5 million in Q1 2026 from $57.3 million in Q1 2025, driven by lower Auryxia revenues.
• Auryxia net product revenues decreased to $36.2 million in Q1 2026 from $43.8 million in Q1 2025, with expectations of further decline due to generic competition.
• Cost of goods sold increased to $12.3 million in Q1 2026 from $7.6 million in Q1 2025, primarily due to inventory write-downs.
• Research and development expenses increased to $14.8 million in Q1 2026 from $9.8 million in Q1 2025.
• Selling, general, and administrative expenses increased to $30.4 million in Q1 2026 from $25.7 million in Q1 2025.
• The company reported a net loss of $9.1 million in Q1 2026, a shift from a net income of $6.1 million in Q1 2025.
• Cash and cash equivalents decreased to $162.6 million as of March 31, 2026, from $184.8 million as of December 31, 2025.

Risks

• Vafseo carries a boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.
• Targeting a hemoglobin level greater than 11 g/dL with Vafseo is expected to further increase the risk of death and thrombotic events.
• Hepatocellular injury has been reported with Vafseo, with elevated ALT, AST, and bilirubin levels observed in some patients.
• Worsening of hypertension and cases of hypertensive crisis have been reported in patients receiving Vafseo.
• Seizures occurred in a percentage of patients treated with Vafseo.
• Serious gastrointestinal erosions, including bleeding and need for transfusions, have been reported.
• The safety of Vafseo has not been established for patients with anemia due to CKD not on dialysis, and its use is not recommended in this setting due to observed increased risks.
• Malignancies were observed in clinical trials, though no evidence of increased carcinogenicity was seen in animal studies.

Future Outlook

Akebia expects its existing cash resources and cash from operations to be sufficient to fund its current operating plan for at least two years. The company anticipates topline data from the VOCAL trial in Q4 2026 and from the VOICE trial in early 2027. A Phase 2 open-label basket study for AKB-097 is expected to initiate in the second half of 2026, with initial data in 2027. A Phase 1 study of AKB-9090 is expected to yield topline data in early 2027.

Management Comments

• "The number of patients on Vafseo increased through the start of the year, and we are further encouraged by trends suggesting continued growth as we leverage improved patient access and adherence as dialysis organizations implement observed dosing protocols."
• "Increasing the breadth and depth of Vafseo prescribing, complemented by our efforts to generate data that will potentially demonstrate its additional clinical benefits, is critical to achieving our goal to make Vafseo standard of care for patients on dialysis."
• "Separately, Im pleased with the progress made to advance our clinical pipeline of kidney disease programs, now with two clinical programs enrolling, including a Phase 2 clinical trial of praliciguat in FSGS."
• "We remain on track with plans to initiate a Phase 2 open-label rare kidney disease basket study in the second half of 2026, evaluating AKB-097 in IgA nephropathy, lupus nephritis and C3 glomerulopathy."

Industry Context

StockSavvy.ai notes that Akebia's Q1 2026 results reflect the ongoing commercialization efforts for Vafseo in the competitive anemia due to CKD market. The company's focus on pipeline development, particularly in rare kidney diseases, aligns with industry trends of seeking specialized treatments. The reported Vafseo revenue growth and patient uptake are positive indicators, but the continued decline in Auryxia revenue highlights the impact of generic competition on established products.

Comparison to Industry Standards

• The economic analysis presented for Vafseo showed a 14.8% lower annual hospitalization cost per patient compared to darbepoetin alfa, based on Medicare cost data.
• The post-hoc analysis of the INNO2VATE program indicated Vafseo achieved statistically significant better outcomes on a composite endpoint of all-cause mortality and hospitalization compared to darbepoetin alfa, a standard-of-care ESA.
• Vafseo's first refill adherence rate of approximately 86% for patients on observed dosing protocols is a key metric for long-term product success in the chronic disease management space.
• The increase in Vafseo prescribers by 28% and patient numbers by 60% in Q1 2026 suggests a positive market penetration trajectory, though direct comparisons to competitors' launch phases are not provided in the filing.

Stakeholder Impact

• Shareholders: The report shows continued revenue growth for Vafseo, a key product, but also a net loss and declining Auryxia revenue, which may impact stock valuation.
• Patients: Vafseo is showing increased adoption and adherence, potentially improving treatment outcomes for anemia due to CKD. The pipeline advancements offer hope for new treatments for rare kidney diseases.
• Healthcare Providers: The company is generating data to support Vafseo's clinical benefits and is advancing pipeline candidates, providing new therapeutic options.
• Creditors: The company's cash position and expectation of sufficient funding for at least two years suggest short-term financial stability.

Next Steps

• Continue to leverage improved patient access and adherence for Vafseo.
• Generate data to potentially demonstrate additional clinical benefits of Vafseo.
• Initiate a Phase 2 open-label rare kidney disease basket study for AKB-097 in the second half of 2026.
• Initiate a Phase 1 study of AKB-9090 (completed in April 2026).
• Report topline data from the VOCAL trial in Q4 2026.
• Report topline data from the VOICE trial in early 2027.
• Report initial data from the AKB-097 Phase 2 study in 2027.
• Report topline data from the AKB-9090 Phase 1 study in early 2027.

Key Dates

Recommendation

The company shows strong growth in its key product, Vafseo, and a promising pipeline. However, the overall revenue decline, net loss, and significant safety warnings associated with Vafseo warrant a cautious 'hold' rating until further clinical data and commercial performance solidify its market position and mitigate risks.

Keywords

Akebia Therapeutics, Vafseo, vadadustat, kidney disease, anemia, CKD, FSGS, financial results